Zobrazeno 1 - 10
of 158
pro vyhledávání: '"James R, Rigas"'
Autor:
Ethan Dmitrovsky, Samuel Waxman, Jonathan M. Kurie, Sarah J. Freemantle, Xi Liu, James R. Rigas, William Nugent, Cherie P. Erkmen, David Johnstone, Marc Seltzer, Gregory J. Tsongalis, Alexander M. Busch, Vincent Memoli, Fabrizio Galimberti, Jobin Cyrus, Tian Ma, Konstantin H. Dragnev
Perspective on This Article from Bexarotene Plus Erlotinib Suppress Lung Carcinogenesis Independent of KRAS Mutations in Two Clinical Trials and Transgenic Models
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04de993e29596306e23331f207ed8327
https://doi.org/10.1158/1940-6207.22524630.v1
https://doi.org/10.1158/1940-6207.22524630.v1
Autor:
Ethan Dmitrovsky, Samuel Waxman, Jonathan M. Kurie, Sarah J. Freemantle, Xi Liu, James R. Rigas, William Nugent, Cherie P. Erkmen, David Johnstone, Marc Seltzer, Gregory J. Tsongalis, Alexander M. Busch, Vincent Memoli, Fabrizio Galimberti, Jobin Cyrus, Tian Ma, Konstantin H. Dragnev
Supplementary Figure S1 from Bexarotene Plus Erlotinib Suppress Lung Carcinogenesis Independent of KRAS Mutations in Two Clinical Trials and Transgenic Models
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::751775a8faff2ebd75a8a5d9f7a22def
https://doi.org/10.1158/1940-6207.22524627
https://doi.org/10.1158/1940-6207.22524627
Autor:
Ethan Dmitrovsky, James R. Rigas, Andres Negro-Vilar, Thomas Hermann, William C. Nugent, Vincent Memoli, Candice C. Black, Lionel D. Lewis, Sumit J. Shah, W. Jeffrey Petty, Konstantin H. Dragnev
Supplementary Data from A Proof-of-Principle Clinical Trial of Bexarotene in Patients with Non–Small Cell Lung Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65a75b74dc859c11835652c0cf704a0d
https://doi.org/10.1158/1078-0432.22441278
https://doi.org/10.1158/1078-0432.22441278
Autor:
Frances A. Shepherd, Tal Z. Zaks, Lance Leopold, Kimberly E. Allen, Habib Hassani, Michael Smylie, James R. Rigas, Jennifer Garst, Afshin Dowlati, Nevena Damjanov, Joseph Aisner, George R. Blumenschein, Helen J. Ross
Purpose: This randomized phase II study was initially designed to test the activity of two dose schedules of lapatinib (GW572016H), an oral, reversible, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b46e80103841eec566f7a61b9767a06e
https://doi.org/10.1158/1078-0432.c.6517636.v1
https://doi.org/10.1158/1078-0432.c.6517636.v1
Autor:
Ethan Dmitrovsky, James R. Rigas, Andres Negro-Vilar, Thomas Hermann, William C. Nugent, Vincent Memoli, Candice C. Black, Lionel D. Lewis, Sumit J. Shah, W. Jeffrey Petty, Konstantin H. Dragnev
Purpose: Bexarotene is a rexinoid (selective retinoid X receptor agonist) that affects proliferation, differentiation, and apoptosis in preclinical studies. The relationship between bexarotene levels and biomarker changes in tumor tissues has not bee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a81d96ae85faab177b3d106c69394db
https://doi.org/10.1158/1078-0432.c.6518382
https://doi.org/10.1158/1078-0432.c.6518382
Autor:
Frances A. Shepherd, Tal Z. Zaks, Lance Leopold, Kimberly E. Allen, Habib Hassani, Michael Smylie, James R. Rigas, Jennifer Garst, Afshin Dowlati, Nevena Damjanov, Joseph Aisner, George R. Blumenschein, Helen J. Ross
Supplementary Data from Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fd3bdd182ae6ad75ba8f901111516c9
https://doi.org/10.1158/1078-0432.22440286.v1
https://doi.org/10.1158/1078-0432.22440286.v1
Autor:
James R. Rigas, Cynthia K. Hahn, Peter E. Kebbekus, Jeremy D. Whyman, Sarah F. Kokko, Sunil Bhatt, Konstantin H. Dragnev
Publikováno v:
Journal of Thoracic Disease. 10:5531-5537
Background: Rexinoids demonstrate anti-proliferative differentiation-inducing activity in multiple cancer types, including NSCLC. Prior studies have shown promising results when combining rexinoids with chemotherapy. This phase I/II study evaluates t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f6fd3845a6968aed29ce07beb38cd7f
https://doi.org/10.21037/jtd.2018.09.10
https://doi.org/10.21037/jtd.2018.09.10
Autor:
Filippo de, Marinis, Yi-Long, Wu, Gilberto, de Castro, Gee-Chen, Chang, Yuh-Min, Chen, Byoung Chul, Cho, Helano C, Freitas, Liyan, Jiang, Sang-We, Kim, Claudio, Martin, Giulio, Metro, Mariano, Provencio, Johan, Vansteenkiste, David, Vicente, Qing, Zhou, Miguel F, Miranda, Nicolaas A, Bakker, James R, Rigas, Parneet K, Cheema
Publikováno v:
Future oncology (London, England). 15(26)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5f7f9b0554e33d3e73a98c4977b29222
https://pubmed.ncbi.nlm.nih.gov/31339357
https://pubmed.ncbi.nlm.nih.gov/31339357
Autor:
David Planchard, Julien Mazieres, James R. Rigas, Bruce E. Johnson, Allison Upalawanna, Benjamin Besse, Tae Min Kim, Pierre-Jean Souquet, Silvia Novello, Bijoyesh Mookerjee, Christina S. Baik, Anthony D'Amelio, Harry J.M. Groen, Elisabeth Quoix, Fabrice Barlesi, Pingkuan Zhang
Publikováno v:
Lancet Oncology, 17(7), 984-993. ELSEVIER SCIENCE INC
Background BRAF mutations act as an oncogenic driver via the mitogen-activated protein kinase (MAPK) pathway in non-small cell lung cancer (NSCLC). BRAF inhibition has shown antitumour activity in patients with BRAF(V600E)-mutant NSCLC. Dual MAPK pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::575a004a61c66cab8f05cb16e3d6c7df
https://doi.org/10.1016/s1470-2045(16)30146-2
https://doi.org/10.1016/s1470-2045(16)30146-2
BACKGROUND Tissue biopsy to identify targetable genomic and immunologic alterations is the mainstay of managing patients with non-small cell lung cancer (NSCLC); however, little is known about the associated economic impact and complication rates. OB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7506e691f981caf95d0a92468ba29d60
https://doi.org/10.2196/preprints.11858
https://doi.org/10.2196/preprints.11858